Brainstorm Cell Analyst Ratings
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating
Maxim Group Maintains Buy on Brainstorm Cell, Lowers Price Target to $10
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Brainstorm Cell Therapeutics (BCLI) and Agilon Health (AGL)
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
No Data